Law360, New York (February 13, 2008, 12:00 AM ET) -- After months of fighting, Eli Lilly & Co. has won its bid to combine a California whistleblower case alleging it marketed its blockbuster anti-psychotic drug Zyprexa for off-label uses with a separate multidistrict litigation pending in a New York district court.
In a transfer order filed Wednesday in the U.S. District Court for the Northern District of California, the Panel on Multidistrict Litigation directed that the case be transferred to the Eastern District of New York for inclusion in the consolidated pretrial proceedings that are currently...
Lilly Wins Bid To Shift Zyprexa Whistleblower Suit
To view the full article, take a free trial now.
